Evidence map›Paper›PMID 39132063›Full record

ArticleGastro hep advances2022

Patient Factors Associated With Gastroesophageal Reflux Disease Diagnostic Evaluation Strategies: A Retrospective Cohort Study Using Real-World Evidence From a Large U.S. Medical Claims Database.

Ravy K Vajravelu, Jennifer M Kolb, Walid F Gellad, Frank I Scott, Anna Tavakkoli, Amit G Singal, David A Katzka, Gary W Falk, Sachin Wani

Erratum issuedAbstract read
In one paragraph

Article in Gastro hep advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. New Techniques to Screen for Barrett Esophagus.Gastroenterology & hepatology · 2023
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Ravy K VajraveluDivision of Gastroenterology, Hepatology and Nutrition, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.
Jennifer M KolbDivision of Gastroenterology, Hepatology and Parenteral Nutrition, VA Greater Los Angeles Healthcare System, David Geffen School of Medicine at UCLA, Los Angeles, California.
Walid F GelladCenter for Health Equity Research Promotion, Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, Pennsylvania.
Frank I ScottDivision of Gastroenterology and Hepatology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
Anna TavakkoliDivision of Gastroenterology and Hepatology, University of Texas Southwestern Medical School, Dallas, Texas.
Amit G SingalDivision of Gastroenterology and Hepatology, University of Texas Southwestern Medical School, Dallas, Texas.
David A KatzkaDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
Gary W FalkDivision of Gastroenterology and Hepatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Sachin WaniDivision of Gastroenterology and Hepatology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.

Funding

TRANSGENIC AND CHIMERIC MOUSE COREP30DK050306 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI REBECCA G WELLS · 1997 to 2026
$32.5M
Weight loss-induced Microbiome and Adipokine Changes in Barrett's EsophagusU54CA163004 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ABRAMS, JULIAN, RUSTGI, ANIL K · 2011 to 2022
$12.5M
Precision Screening for Hepatocellular Carcinoma in Patients with CirrhosisR01CA222900 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI SINGAL, AMIT · 2018 to 2023
$2.4M
Evaluation of multiple medication exposures concurrently using a novel algorithmK08DK119475 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI VAJRAVELU, RAVY KUPPALAPALLE · 2019 to 2023
$797k
A Multicenter Randomized Controlled Trial of Surveillance versus. Endoscopic Therapy for Barretts Esophagus with Low-grade Dysplasia: The SURVENT TrialU34DK124174 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI DURKALSKI, VALERIE L, SHAHEEN, NICHOLAS J · 2020 to 2020
$384k
NCI NIH HHS R01 CA222900NCI NIH HHS U54 CA163004NIDDK NIH HHS K08 DK119475NIDDK NIH HHS P30 DK050306NIDDK NIH HHS U34 DK124174
6 · The paper itself

Abstract

Background and Aims: Barrett's esophagus (BE) screening is not highly utilized in the United States, and there are few data describing providers' approach to screening. To fill this gap and guide the implementation of future BE screening strategies, we studied evaluation practice patterns for gastroesophageal reflux disease (GERD) by nongastroenterologists. Methods: We performed a retrospective cohort study of patients with chronic GERD using health claims data from the United States between 2005 and 2019. We used up to 5 years of data after the diagnosis of chronic GERD to determine patient factors associated with completion of a gastroenterology encounter. We also identified patient factors associated with whether the first gastroenterology encounter was a direct-access upper endoscopy or an office visit. Results: We identified 484,023 patients diagnosed with chronic GERD by a nongastroenterology provider. The cumulative incidence of completing a gastroenterology encounter within 5 years was 38.7%. Gastrointestinal symptoms, such as dysphagia (adjusted hazard ratio [aHR] = 2.11, 95% confidence interval [CI] = 1.94-2.30), abdominal pain (aHR = 1.89, 95% CI = 1.85-1.94), and melena (aHR = 1.73, 95% CI = 1.65-1.82), were strongly associated with completion of a gastroenterology encounter. The patient factors strongly associated with direct-access upper endoscopy included dysphagia (aHR = 1.68, 95% CI = 1.52-1.85), weight loss (aHR = 1.46, 95% CI = 1.28-1.63), and melena (aHR = 1.42, 95% CI = 1.28-1.56). Conclusion: A total of 38.7% of patients with chronic GERD complete a gastroenterology encounter within 5 years of diagnosis, and gastrointestinal alarm symptoms are the most strongly associated factors for receiving gastroenterology care. These findings highlight the importance of incorporating primary care providers in the development of new BE screening programs.

Indexed as

Barrett’s EsophagusEsophageal AdenocarcinomaHealth Care UtilizationUpper Endoscopy

Identifiers

PMID39132063
PMCPMC11307463

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.